GlassScriptPhysician profile
Milind M Vaze
NPI 1548256738
$9,211.52
in general payments reported to CMS, 2019-2025
41 companies · $1,832 in 2025
The $1,832 reported for 2025 was more than what 77% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,560 · 2020: $547 · 2021: $1,347 · 2022: $1,165 · 2023: $947 · 2024: $1,814 · 2025: $1,832.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,566 · Education: $26.96.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,566.06 |
| Education | $26.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,399.18 | 2019-2025 | Creon, Linzess, Viberzi |
| Gilead Sciences, INC. | $1,041.19 | 2019-2025 | Livdelzi |
| Takeda Pharmaceuticals U.S.A., INC. | $742.73 | 2019-2025 | Entyvio, Eohilia |
| Janssen Biotech, INC. | $640.85 | 2019-2025 | Tremfya, Simponi, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $486.16 | 2019-2025 | Xifaxan, Trulance |
| Braintree Laboratories, INC. | $446.72 | 2019-2025 | Suflave, Sutab |
| Redhill Biopharma INC. | $338.25 | 2020-2024 | Talicia, Movantik, Aemcolo |
| Novo Nordisk INC | $276.32 | 2020-2025 | Wegovy |
| Celgene Corporation | $258.40 | 2021-2024 | Zeposia |
| Ironwood Pharmaceuticals, INC | $228.27 | 2020-2024 | Linzess |
| Merck Sharp & Dohme LLC | $227.29 | 2020-2025 | Dificid, Pifeltro |
| Intercept Pharmaceuticals, INC. | $220.47 | 2019-2025 | |
| Madrigal Pharmaceuticals | $216.09 | 2025 | Rezdiffra |
| Shionogi INC | $214.78 | 2019-2020 | |
| Qol Medical, LLC | $186.89 | 2019-2024 | Sucraid, Sucraid |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $146.21 | 2023-2025 | |
| Viiv Healthcare Company | $125.00 | 2021 | |
| Celltrion USA INC. | $95.10 | 2024-2025 | Vegzelma, Zymfentra |
| Medtronic, INC. | $92.35 | 2021-2024 | Gi Genius |
| Ardelyx, INC. | $91.92 | 2023-2025 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $74.03 | 2024-2025 | Dupixent |
| Lilly USA, LLC | $67.68 | 2024 | Omvoh, Mounjaro |
| Intra-Sana Laboratories | $51.89 | 2023 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Aimmune Therapeutics, INC. | $46.86 | 2025 | Zenpep |
| Abbott Laboratories | $46.45 | 2024-2025 | Freestyle Libre 3 |
| Digestive Care, INC. | $45.61 | 2024 | Pertzye |
| Allergan, INC. | $43.73 | 2019-2020 | |
| Radius Health, INC. | $43.57 | 2020-2021 | |
| Boston Scientific Corporation | $42.07 | 2019-2020 | |
| Exact Sciences Corporation | $39.62 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Pharmacosmos Therapeutics INC. | $37.18 | 2024 | Monoferric |
| Ferring Pharmaceuticals INC. | $28.11 | 2019 | |
| Genzyme Corporation | $27.57 | 2025 | |
| Almatica Pharma LLC | $23.38 | 2025 | Teriparatide, Loreev Xr |
| Ipsen Biopharmaceuticals, INC | $22.00 | 2024 | Iqirvo |
| Phathom Pharmaceuticals, INC. | $21.78 | 2024 | Voquezna |
| E.R. Squibb & Sons, L.L.C. | $18.01 | 2021 | |
| Sandoz INC. | $17.86 | 2024 | Hyrimoz |
| Evoke Pharma, INC. | $14.93 | 2021 | |
| Shire North American Group INC | $13.41 | 2019 | |
| Concordia Pharmaceuticals INC. | $11.61 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Milind Vaze listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.